deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03206203

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer

Sponsor: Genentech, Inc.

Conditions HER2 Negative Invasive Breast Cancer Stage IV Breast Cancer Triple Negative Breast Cancer
Interventions Atezolizumab Carboplatin Laboratory Biomarker Quality-of-Life Assessment
Updated 19 times since 2017 Last updated: Nov 25, 2024 Started: Aug 29, 2017 Primary completion: Nov 30, 2022 Completion: Oct 4, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HER2 Negative and Invasive Breast Cancer, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 19 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Apr 2020 · 8 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jan 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Oct 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. May 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  9. Aug 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Nov 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  11. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  13. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  14. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • National Cancer Institute (NCI)
  • Vanderbilt-Ingram Cancer Center
Data source: Vanderbilt-Ingram Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations